Search Results - "Ziras, N."

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) by Mavroudis, D., Saloustros, E., Malamos, N., Kakolyris, S., Boukovinas, I., Papakotoulas, P., Kentepozidis, N., Ziras, N., Georgoulias, V.

“…Adjuvant trastuzumab in combination with chemotherapy improves survival of women with HER2-positive early breast cancer. In this study, we compared 12 versus 6…”
Get full text

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project by Souglakos, J., Boukovinas, I., Kakolyris, S., Xynogalos, S., Ziras, N., Athanasiadis, A., Androulakis, N., Christopoulou, A., Vaslamatzis, M., Ardavanis, A., Emmanouilides, C., Bompolaki, I., Kourousis, C., Makrantonakis, P., Christofyllakis, C., Athanasiadis, E., Kentepozidis, N., Karampeazis, A., Katopodi, U., Anagnosopoulos, A., Papadopoulos, G., Prinarakis, E., Kalisperi, A., Mavroudis, D., Georgoulias, V.

“…The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) aimed to investigate whether a 3 months (3M) of oxaliplatin/fluoropyrimidine-based…”
Get full text

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) by Souglakos, J, Androulakis, N, Syrigos, K, Polyzos, A, Ziras, N, Athanasiadis, A, Kakolyris, S, Tsousis, S, Kouroussis, Ch, Vamvakas, L, Kalykaki, A, Samonis, G, Mavroudis, D, Georgoulias, V

“…To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs…”
Get full text

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volume 26, Issue 7, July 2015, Pages 1333–1340 by Mavroudis, D., Saloustros, E., Malamos, N., Kakolyris, S., Boukovinas, I., Papakotoulas, P., Kentepozidis, N., Ziras, N., Georgoulias, V.

Get full text

Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer by Mylonakis, N, Athanasiou, A, Ziras, N, Angel, J, Rapti, A, Lampaki, S, Politis, N, Karanikas, C, Kosmas, C

“…Abstract Background Lipoplatin is a new liposomal cisplatin designed to reduce cisplatin toxicities without reducing efficacy. In the present randomized phase…”
Get full text

Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) by Mavroudis, D., Matikas, A., Malamos, N., Papakotoulas, P., Kakolyris, S., Boukovinas, I., Athanasiadis, A., Kentepozidis, N., Ziras, N., Katsaounis, P., Saloustros, E., Georgoulias, V.

“…Sequential administration of anthracycline and taxane is the current standard of care adjuvant regimen for node-positive early breast cancer. Due to long-term…”
Get full text

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer by STATHOPOULOS, G. P, SYRIGOS, K, ANDROULAKIS, N, KOTSAKIS, A, SAMONIS, G, GEORGOULIAS, V, ARAVANTINOS, G, POLYZOS, A, PAPAKOTOULAS, P, FOUNTZILAS, G, POTAMIANOU, A, ZIRAS, N, BOUKOVINAS, J, VARTHALITIS, J

“…Our purpose was to determine the response rate and median and overall survival of gemcitabine as monotherapy versus gemcitabine plus irinotecan in advanced or…”
Get full text

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) by Souglakos, J, Ziras, N, Kakolyris, S, Boukovinas, I, Kentepozidis, N, Makrantonakis, P, Xynogalos, S, Christophyllakis, Ch, Kouroussis, Ch, Vamvakas, L, Georgoulias, V, Polyzos, A

“…Background: To compare the efficacy and safety of CAPIRI+bevacizumab (Bev) in comparison with FOLFIRI+Bev as first-line treatment for patients with metastatic…”
Get full text

The role of bevacizumab plus front-line chemotherapy in patients with malignant ascites of ovarian cancer by Nikolaou, M., Ziras, N., Athanasiadis, I., Ardavanis, A., Vaslamatzis, M., Kentepozidis, N., Makrantonakis, P., Christopoulou, A.N., Michalaki, V., Polizos, A., Emmanouilidis, C., Georgoulias, V.

Get full text

A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer by Kontopodis, E., Kotsakis, A., Kentepozidis, N., Syrigos, K., Ziras, N., Moutsos, M., Filippa, G., Mala, A., Vamvakas, L., Mavroudis, D., Georgoulias, V., Agelaki, S.

“…Background Bortezomib is a selective reversible proteasome inhibitor with proapoptotic effects. Preclinical and phase I clinical data suggest activity of…”
Get full text

Prevention and prophylaxis of thrombosis in cancer patients by Tsoukalas, N.G., Papakotoulas, P., Christopoulou, A.N., Ardavanis, A., Koumakis, G., Papandreou, C., Papatsimpas, G., Papakostas, P., Andreadis, C., Aravantinos, G., Ziras, N., Kalofonos, H., Samantas, E., Sougleri, M., Makrantonakis, P., Pentheroudakis, G., Athanasiadis, A., Bournakis, E., Varthalitis, I.I., Boukovinas, I.

Get full text

Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG) by Matikas, A., Kentepozidis, Ν., Ardavanis, A., Vaslamatzis, M., Polyzos, A., Emmanouilides, Ch, Katsaounis, P., Koinis, F., Xynogalos, S., Christopoulou, A., Ziras, N., Tegos, Th, Prinarakis, E., Hatzidaki, D., Georgoulias, V., Kotsakis, A.

“…Introduction The addition of bevacizumab to the first-line chemotherapy of advanced non-small cell lung cancer (NSCLC) of non-squamous histology has been shown…”
Get full text

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer by Mavroudis, D., Papakotoulas, P., Ardavanis, A., Syrigos, K., Kakolyris, S., Ziras, N., Kouroussis, C., Malamos, N., Polyzos, A., Christophyllakis, C., Kentepozidis, N., Georgoulias, V.

“…Background: The purpose of this study was to compare docetaxel plus epirubicin versus docetaxel plus capecitabine combinations as front-line treatment in women…”
Get full text

Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG) by Vamvakas, L, Athanasiadis, A, Karampeazis, A, Kakolyris, S, Polyzos, A, Kouroussis, Ch, Ziras, N, Kalbakis, K, Georgoulias, V, Souglakos, J

“…Abstract Background A subgroup analysis of oxaliplatin (LOHP) + irinotecan (CPT-11) + 5-fluorouracil (5FU) and leucovorin (LV) (FOLFOXIRI regimen) versus…”
Get full text

A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer by Karachaliou, N., Ziras, N., Syrigos, K., Tryfonidis, K., Papadimitraki, E., Kontopodis, E., Bozionelou, V., Kalykaki, A., Georgoulias, V., Mavroudis, D.

“…Objective To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated…”
Get full text

Metabolic syndrome and Cancer: Do they share common molecular pathways? by Veniou, E., Sofatzis, I., Kalantzis, I., Karakosta, M., Logothetis, M., Lianos, E., Ziras, N.

“…Metabolic syndrome, a clustering of risk factors including obesity, has emerged as a global health plague. A lot of epidemiological and clinical evidence…”
Get full text

Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature by Kaldrymides, Ph, Kostoglou-Athanassiou, I., Gkountouvas, A., Veniou, E., Ziras, N.

“…Tyrosine kinase receptors have been implicated in thyroid cancer. Therefore, tyrosine kinase inhibitors may be used for the treatment of advanced metastatic…”
Get full text

Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study by Stathopoulos, G. P., Syrigos, K., Polyzos, A., Fountzilas, G., Rigatos, S. K., Ziras, N., Potamiannou, A., Tsiakopoulos, I., Androulakis, N., Aravantinos, G., Athanasiadis, A., Papakotoulas, P., Georgoulias, V.

“…Purpose: To evaluate the efficacy and toxicity of gemcitabine (GEM) combined with capecitabine (CAP) in untreated patients with inoperable or metastatic…”
Get full text

Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group by Boukovinas, I, Androulakis, N, Vamvakas, L, Papakotoulas, P, Ziras, N, Polyzos, A, Kalykaki, A, Kotsakis, A, Xenidis, N, Gioulmbasanis, I, Mavroudis, D, Georgoulias, V

“…Background: The purpose of this study was to investigate the toxicity and efficacy of the sequential administration of gemcitabine (GMB) in combination with…”
Get full text

Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial by PECTASIDES, D, GLOTSOS, J, BOUNTOUROGLOU, N, KOULOUBINIS, A, MITAKIDIS, N, KARVOUNIS, N, ZIRAS, N, ATHANASSIOU, A

“…To evaluate the efficacy and toxicity of a combination of weekly docetaxel, gemcitabine and cisplatin in advanced transitional cell carcinoma (TCC) of the…”
Get full text